Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. Additionally, our philanthropic programs have given new hope to some of the world’s most vulnerable communities and the preservation of our natural resources represents one of our key commitments.
Our BioPharma strategy uniquely combines the best elements of a traditional pharmaceutical company with the entrepreneurial spirit and agility of a leading-edge biotech company – and our strategy is working. Since 2002, we have delivered 13 key new products to patients with serious diseases, four of these medicines are biologic products, and our pipeline continues to deliver. In 2011, we received approvals for three new medicines – an impressive number for a single year; and we outperformed most big pharma companies, diversified companies and pure biotech companies. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through our development pipeline and we are recognized as having one of the most productive pipelines in the industry.
Research and Development
Research is at the forefront of the drug discovery and development process at Bristol-Myers Squibb. Our goal is to discover novel medicines that will benefit patients with serious unmet medical needs and develop these to Proof of Confidence (POC). We are drug hunters, we seek to design and deliver a robust pipeline of high quality drug candidates driven by internal Discovery efforts and enhanced by both external partnerships and our String of Pearl transactions.
Research begins with the identification and validation of new biological targets involved in disease processes by using screening technologies to discover candidate compounds that can modulate the target and change the pathological process. Promising candidate compounds (both small molecules and biologics), undergo drug design and optimization before entering non-clinical safety testing. In addition to understanding potential toxicity issues of all drug candidates, metabolism and pharmaceutical acceptability are studied and structural alterations are made by medicinal chemists striving to produce candidate drugs with favorable benefit/risk profiles.
Our early development group conducts studies to characterize the profile of a new medicine in the human body, which is the first step in establishing whether it will be safe and effective for patients. The first studies in humans establish how the new medicine is absorbed and distributed by the body. A safe dosage is established and side effects are monitored. We also study pharmacological profiles for all phases of clinical research. Medical care is becoming increasingly more personalized as our understanding of diseases at the molecular level has advanced, and we use advanced technologies to identify biomarkers, and develop assays for the use of these biomarkers in clinical studies.
Scientific innovation is a keystone of our culture, and this is incorporated into all our efforts. In BMS Research we have world class scientific expertise in both disease areas and technology platforms. We welcome motivated, innovative, curious scientists who enjoy working in diverse collaborative teams to achieve Bristol-Myers Squibb’s mission to develop and deliver drug therapies to help patients prevail over serious unmet medical needs.